1)Chang JT : Pathophysiology of Inflammatory Bowel Diseases. N Engl J Med 383:2652-2664,2020
2)Serada S, Fujimoto M, Ogata A, et al : iTRAQ-based proteomic identification of leucine-rich alpha-2 glycoprotein as a novel inflammatory biomarker in autoimmune diseases. Ann Rheum Dis 69:770-774,2010
3)Naka T, Fujimoto M : LRG is a novel inflammatory marker clinically useful for the evaluation of disease activity in rheumatoid arthritis and inflammatory bowel disease. Immunol Med 41:62-67,2018
4)Serada S, Fujimoto M, Terabe F, et al : Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis. Inflamm Bowel Dis 18:2169-2179,2012
5)Lawrence JD, Amanda L, Shimena L et al: Leucine Rich α-2 Glycoprotein: A Novel Neutrophil Granule Protein and Modulator of Myelopoiesis. PLoS One 12:e0170261,2017
6)Shinzaki S, Matsuoka K, Iijima H, et al : Leucine-rich Alpha-2 Glycoprotein is a Serum Biomarker of Mucosal Healing in Ulcerative Colitis. J Crohns Colitis 11:84-91,2017
7)Shinzaki S, Matsuoka K, Tanaka H, et al : Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab : PLANET study. J Gastroenterol 56:560-569,2021
8)Yanai S, Shinzaki S, Matsuoka K, et al : Leucine-Rich Alpha-2 Glycoprotein May Be Predictive of the Adalimumab Trough Level and Antidrug Antibody Development for Patients with Inflammatory Bowel Disease : A Sub-Analysis of the PLANET Study. Digestion 102:929-937,2021
9)Kawamoto A, Takenaka K, Hibiya S, et al : Serum Leucine-Rich α2 Glycoprotein : A Novel Biomarker For Small Bowel Mucosal Activity in Crohn's Disease. Clin Gastroenterol Hepatol S1542-3565(21)00700-X,2021
10)Yasutomi E, Inokuchi T, Hiraoka S, et al : Leucine-rich alpha-2 glycoprotein as a marker of mucosal healing in inflammatory bowel disease. Sci Rep 11:11086,2021